Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Annette Hasenburg Prof., Dr, med

Annette Hasenburg Prof., Dr, med

Director, Obstetrics and Gynecology, Mainz University Medical Center, Mainz, Germany

Dr. Annette Hasenburg is the Director of Obstetrics and Gynecology at Mainz University Medical Center in Mainz, Germany. She is Head of the ESGO (European Society of Gynaecologic Oncology) Task Force Psycho-Oncology and is on the board of directors of the Institute of Sexuality and Health of the University Freiburg in Freiburg, Germany.

Dr. Hasenburg received her medical degree from Ruhr-University, Bochum, Germany, where she also received residency training in internal medicine (Evangelisches Krankenhaus Herne) and obstetrics and gynecology (Marienhospital Herne). She received specialist training and qualification in psychotherapy at the Institute of Psychotherapy and Psychosomatic Medicine in Düsseldorf. She completed a postdoctoral fellowship in the Department of Obstetrics and Gynecology, Oncology Division, at Baylor College of Medicine in Houston, Texas.

Since 2018, Dr. Hasenburg has been on the Board of Directors of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie) and since 2020 on the Board of Directors of the DGGG (Deutsche Gesellschaft Gynäkologie und Geburtshilfe).

Disclosures

  • Honoraria: AstraZeneca; Celgen; GSK; LEO Pharma; MedConcept GmbH; Med update GmbH; Medicultus; Pfizer; Promedicis GmbH; Softconsult; Roche Pharma AG; Streamedup! GmbH; Tesaro Bio Germany GmbH
  • Advisory roles: AstraZeneca; GSK; LEO Pharma; PharmaMar; Promedicis GmbH; Roche Pharma AG; Tesaro Bio Germany GmbH; MSD (Merck Sharp & Dohme) GmbH

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Oncology: KEYNOTE-A18 — Adding Pembrolizumab to Chemoradiotherapy for Locally Advanced Cervical Cancer
  2. ESMO 2024: Recommendations From Dr. Annette Hasenburg for Gynecological Cancer
  3. Atezolizumab and Chemotherapy for Advanced or Recurrent Endometrial Cancer
  4. Pembrolizumab With Chemoradiotherapy Followed by Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
  5. Simple vs Radical Hysterectomy in Women With Low-Risk Cervical Cancer
  6. Neoadjuvant Chemotherapy Plus Camrelizumab for Locally Advanced Cervical Cancer
  7. Atezolizumab Plus Bevacizumab and Chemotherapy for Metastatic, Persistent, or Recurrent Cervical Cancer
  8. ESMO 2023: Recommendations From Dr. Annette Hasenburg for Gynecological Cancer
  9. ASCO 2023: Abstract Recommendations From Prof. Dr. Annette Hasenburg for Gynecologic Oncology
  10. 2022 Top Story in Oncology: Results From the Phase II KEYNOTE-158 Study

Elsewhere

Most Read This Week

Recently Updated